
The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are poorly understood. The EMPA-KIDNEY trial was designed to assess the impact of treatment with empagliflozin in a broad range of such patients. A total of 6609 patients underwent randomization. Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.
Like
Save
Share